Deeper Knowledge, Faster

  • Plan your formulary budget
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Argus Health
Express Scripts
Harvard Business School

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,882,721

« Back to Dashboard

Which drugs does patent 8,882,721 protect, and when does it expire?

Patent 8,882,721 protects ADLYXIN and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.

Summary for Patent: 8,882,721

Title:Drive assembly suitable for use in a drug delivery device and drug delivery device
Abstract: A drive assembly for use in a drug delivery device is proposed, the drive assembly comprising: a housing having a proximal end and a distal end; an axis extending between the proximal end and the distal end; at least one drive member; a piston rod adapted to be driven along the axis by the drive member; an indicator adapted to provide positional information about a position of the piston rod relative to the proximal end, wherein the indicator and the piston rod are configured to convert a movement of the piston rod with respect to the housing into a rotational movement of the indicator. Additionally, a drug delivery device comprising the drive assembly is provided for.
Inventor(s): Jones; Matthew Meredith (Warwick, GB), Plumptre; David Aubrey (Droitwich, GB)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:12/991,471
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi-aventis Us
SOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes8,882,721► SubscribeY
Sanofi-aventis Us
SOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes8,882,721► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,882,721

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08009260May 20, 2008
08011676Jun 27, 2008
PCT Information
PCT FiledMay 09, 2009PCT Application Number:PCT/EP2009/003310
PCT Publication Date:November 26, 2009PCT Publication Number: WO2009/141067

International Patent Family for Patent: 8,882,721

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina073447► Subscribe
Australia2009250106► Subscribe
BrazilPI0912835► Subscribe
Canada2724763► Subscribe
China102099073► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Queensland Health
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:

Google Plus